Risk factors for patent ductus arteriosus in preterm neonates
Abstract
Background The reported prevalences of patent ductus arteriosus
(PDA) in preterm neonates vaty, and are currently unknown in
Palembang. Birth weight, ges tational age, asphyxia, histoty of
antenatal steroid use, hyaline membrane disease (HMD), race
and ethnicity, are potential risk factors for PDA.
Objective To determine the prevalence of PDA and its risk
factors in preterm neonates at Mohammad Hoesin Hospital,
Palembang.
Methods This cross-sectional study was conducted from October
2011 to April 2012. Echocardiographic examinations were
performed on 242 preterm neonates aged 15 hours to 7 days. Data
was taken from medical records and interviews, and analyzed by
Chi square and logistic regression analyses.
Results Patent ductus arteriosus was found in 142 (58.7%)
preterm neonates with a prevalence ratio of 1.43. Neonates with
birthweight ::;;2,000 grams tended to have 1.9 (95% CI 1.17 to
3.32) rimes higher risk for PDA (P=0.01). Neonates ::;;JO weeks
gestation were also at 1.9 rimes higher risk for PDA (P=0.16).
Probabilities for PDA occurrence in neonates with asphyxia,
without antenatal corticosteroids and HMD were 1.6 (95%
CI 1.13 to 3.36) rimes, 1.3 (95%CI 0.73 to 2.50) times and 2.2
(95%CI 1.29 to 3.72) rimes higher risk for PDA, respectively
(P=0.22, 0.41, and 0.005, respectively).
Conclusion Birth weight and HMD are statistically significant
risk factors of PDA, but the more significant one is HMD.
References
Becker SM, Alhalees Z, Molina C, Paterson RM. Consanguinity and congenital heart disease in Saudi Arabia. AmJ Med Genet. 2001;99:8-13.
Botto LD, Lynberg MC, Erickson JD. Congenital hear defects, maternal feb rile illness, and multivitamin use: a population-based study. Epidemiology. 2001;12:485-90.
National Birth Defects Prevention Network (NBDPN).Birth defects surveillance data from selected states, 1998,2002. Birth Defects Research Part A 2005;73: 759-852.
Texas Department of State Health Services. Texas birth defects registry report of birth defects among 1999,2002 deliveries. Texas: Department of state health services birth defect epidemiology and surveillance.; 2005. p.1-8.
Benson LN. The arterial duct: its persistence and its patency. In: Anderson RH, Baker EJ, Penny DJ, Redington AD, Rigby ML, Wernovsky G, editors. Pediatric cardiology. 3rd ed. Philadelphia: Churchill Livingston; 2010. p.875-93.
Bernstein D. The cardiovascular system. In: Behrman WE, Kliegman R, Arvin AM, editors. Nelson textbook of pediatrics. 18th ed. Philadelphia: W.B. Saunders Company; 2008. p.1851-995.
Park MK. Pediatric cardiology for practitioner. 5th ed. Philadelphia: Mosby Elsevier; 2008. p.159-228.
Department of state health services birth defects epidemiology and surveillance. Birth defect risk factor series: patent ductus arteriosus. Texas: Department of state health services birth defects epidemiology and surveillance; 2006. p.1-8.
Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, et al. Long,tenn effects of indomethacin prophylaxis in extremely-Low-birth-weight neonates. N Engl J Med. 2001;344:1966-72.
Deselina B, Putra ST, Suradi R. Prevalence of patent ductus arteriosus in premature neonates at the Neonatal Ward, Cipto Mangunkusumo Hospital, Jakarta. Paediatr Indones. 2004;44:223-7.
Kumar P, Seshadri R, Grobman WA. N eurodevelop , mental outcome of very Low birth weight neonates after multiple courses of antenatal corticosteroids. J Soc Gynecol Investig. 2004;11:483-7.
The EXPRESS group. Incidence of and risk factors for neonatal morbidity after active perinatal care: extremely preterm neonates study in Sweden (EXPRESS). Acta Paediatr. 2010;99:978-92.
Coceani F, Liu YA, Seidlitz E, Kelsey L, Kuwaki T, Ackerley C, et al. Endothelin A receptor is necessary for O2 constriction but not closure of ductus arteriosus. Am J Physiol Heart Circ Physiol. 1999;277:1521-31.
Lee SK, McMillan DD, Ohlsson A, Pendray M, Synnes A, Whyte R, et al. Variations in practice and outcomes in the Canadian NICU network: 1996-1997. Pediatrics. 2000;106:1070-9.
Pees C, Obladen M. Epidemiology of persisting ductus in pretenn neonates. In: Obladen M, Koehne P, editors. Interventions for persisting ductus arteriosus in the preterm neonate. Heidelberg: Springer Medizin Verlag; 2005. p.19-23.
Xiao-Yu Q, Xian-Feng Z, Yi Q, Bin-Zhi T, De-Zhi M. Risk factors for patent ductus arteriosus in neonates. Chin J Con temp Pediatr. 2011;13:388-91.
Leonhardt A, Strehl R, Barth H, Seyberth HW. High efficacy and minor renal effects of indomethacin treatment during individualized fluid intake in premature neonates with patent ductus arteriosus. Acta Paediatr. 2004;93:233-40.
Van Ovenneire B, Chemtob S. The phannacologic closure of the patent ductus arteriosus. Semin Fetal Neonatal Med. 2005;10:177-84.
Dani C, Bertini G, Corsini I, Elia S, Vangi V, Pratesi S, et al. The fate of ductus arteriosus in neonates at 23-27 weeks of gestation: from spontaneous closure to ibuprofen resistance. Acta Paediatr. 2008;97:1176-80.
Masyur M, Amir I, Putra ST, Tumbelaka AR. Echocardiographic patterns in asphyxiated neonates. Pediatr Indones. 2009;49:214-8.
Mori R, Kusuda S, Fujimura M, Neonatal Research Network Japan. Antenatal corticosteroid promote survival of extremely pretenn neonates born at 22 to 23 weeks of gestation. J Pediatr. 2011;159:110-4.
Bevilacqua E, Brunelli R, Anceschi MM. Review and meta-analysis: benefits and risks of multiple courses of antenatal corticosteroids. J Matern Fetal Neonatal Med. 2010;23:244-60.
Clyman RI. Mechanisms regulating the ductus arteriosus. Biol Neonate. 2006;89:330-5.
Kachel W. Persisting ductus arteriosus and respiratory problems. In: Obladen M, Koehne P, editors. Inter, ventions for persisting ductus arteriosus in the pretenn neonate. Heidelberg: Springer Medizin Verlag; 2005. p. 26-30.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Accepted 2016-08-31
Published 2014-06-30
